A Danish government agency has committed €2.47m to a resveratrol study that will investigate multiple metabolic syndrome endpoints for the antioxidant including obesity, type-2 diabetes and osteoporosis.
The five-year, human research project is sponsored by the Danish Council for Strategic Research will be the longest ever completed to date using resveratrol and add to a growing body of work for the nutrient. Danish supplier Fluxome will provide the resveratrol extract.
